MPT, melphalan, prednisone, and thalidomide; Rd cont, lenalidomide plus low-dose dexamethasone until disease progression; Rd18, lenalidomide plus low-dose dexamethasone for 18 cycles; Rd pooled, Rd cont and Rd18 patients combined; TE, treatment emergent. Microbiology of TE Infections by Treatment Arm During the First 4 and 18 Months of Treatment in Supplemental Table 4. the FIRST Trial 0-4 Months 0-18 Months TE Infections, n Rd Pooled MPT Total Rd Pooled MPT Total Grade 3 Infections ≥ Bacterial 35 18 53 78 24 102 Clostridia 5 4 9 8 5 13 Enterococcal 0 0 0 0 1 1 Escherichia 4 0 4 6 1 7 Klebsiella 0 2 2 1 2 3 Legionella 0 0 0 3 1 4 Neisseria 2 0 2 2 0 2 Pseudomonal 2 4 6 3 5 8 Salmonella 0 0 0 3 0 3 Staphylococcal 8 1 9 17 1 18 Streptococcal 10 1 11 14 1 15
MPT, melphalan, prednisone, and thalidomide; Rd cont, lenalidomide plus low-dose dexamethasone until disease progression; Rd18, lenalidomide plus low-dose dexamethasone for 18 cycles; Rd pooled, Rd cont and Rd18 patients combined; TE, treatment emergent. Supplemental Table 4. Microbiology of TE Infections by Treatment Arm During the First 4 and 18 Months of Treatment in the FIRST Trial TE Infections, n 0-4 Months 0-18 Months Rd Pooled MPT Total Rd Pooled MPT Total Grade ≥ 3 Infections Bacterial Clostridia Enterococcal Escherichia Klebsiella Legionella Neisseria Pseudomonal Salmonella Staphylococcal Streptococcal 35 5 0 4 0 0 2 2 0 8 10 18 4 0 0 2 0 0 4 0 1 1 53 9 0 4 2 0 2 6 0 9 11 78 8 0 6 1 3 2 3 3 17 14 24 5 1 1 2 1 0 5 0 1 1 102 13 1 7 3 4 2 8 3 18 15
41375_2018_133_MOESM1_ESM.docx